浏览全部资源
扫码关注微信
1.甘肃中医药大学第一临床医学院,兰州 730030
2.甘肃省人民医院中西医结合免疫风湿科,兰州 730030
硕士研究生。研究方向:风湿免疫学。E-mail:2818615593@qq.com
主任医师,硕士生导师,博士。研究方向:风湿免疫学。E-mail:zshlz1973@126.com
纸质出版日期:2024-03-15,
收稿日期:2023-07-02,
修回日期:2024-02-17,
扫 描 看 全 文
杨晓蓉,周淑红,郭莉江等.艾拉莫德应用于结缔组织病的作用机制与临床研究进展 Δ[J].中国药房,2024,35(05):629-634.
YANG Xiaorong,ZHOU Shuhong,GUO Lijiang,et al.Mechanism of action and clinical research progress of iguratimod in connective tissue diseases[J].ZHONGGUO YAOFANG,2024,35(05):629-634.
杨晓蓉,周淑红,郭莉江等.艾拉莫德应用于结缔组织病的作用机制与临床研究进展 Δ[J].中国药房,2024,35(05):629-634. DOI: 10.6039/j.issn.1001-0408.2024.05.21.
YANG Xiaorong,ZHOU Shuhong,GUO Lijiang,et al.Mechanism of action and clinical research progress of iguratimod in connective tissue diseases[J].ZHONGGUO YAOFANG,2024,35(05):629-634. DOI: 10.6039/j.issn.1001-0408.2024.05.21.
艾拉莫德作为一种新型免疫抑制剂,可通过抑制炎症细胞增殖和减少炎症细胞因子释放的方式介导抗炎信号通路,发挥抗炎作用;可通过影响免疫细胞增殖及免疫因子表达,减少机体免疫复合物的产生及沉积,发挥调节免疫作用;可通过介导Wnt/
β
-连环蛋白、Toll样受体4/核因子κB和护骨因子/核因子κB受体活化因子配体等信号通路调节骨代谢,发挥骨保护作用;可通过抑制转化生长因子β
1
/Smad2/3信号通路及肿瘤坏死因子α、白细胞介素1、白细胞介素6和基质金属蛋白酶9等炎症细胞因子在肺组织的表达并抑制胶原蛋白及纤连蛋白的表达,发挥抑制肺纤维化作用。其疗效及安全性在类风湿性关节炎和原发性干燥综合征的临床应用中已得到肯定并纳入了疾病的诊疗规范中;其在系统性红斑狼疮和强直性脊柱炎等其他结缔组织病的临床应用过程中同样表现出良好的疗效,且尚未发现明显的安全隐患。
As a new type of immunosuppressant,iguratimod can mediate the anti-inflammatory signaling pathway by inhibiting the proliferation of inflammatory cells and reducing the release of inflammatory cytokines, and play the role of anti-inflammatory. It can affect the proliferation of immune cells and the expression of immune factors,reduce the production and deposition of immune complexes in the body,and play the role of immune regulation. It can regulate bone metabolism by mediating signaling pathways such as Wnt/
β
-catenin,Toll-like receptor 4/nuclear factor-κB and osteoprotegerin/nuclear factor-κB receptor activating factor ligand, and play a role in bone protection. It can inhibit pulmonary fibrosis by inhibiting the expression of transforming growth factor β
1
/Smad2/3 signaling pathway,tumor necrosis factor-α,interleukin-1,interleukin-6,matrix metalloproteinase-9 and other inflammatory cytokines in lung tissue,and inhibiting the expression of collagen and fibronectin. Its efficacy and safety have been confirmed in the clinical application of rheumatoid arthritis and primary Sjogren syndrome and included in the diagnosis and treatment of the disease. It has also shown good efficacy in the clinical application of other connective tissue diseases such as systemic lupus erythematosus and ankylosing spondylitis,and no obvious safety risks have been found.
艾拉莫德结缔组织病作用机制临床应用
connective tissue diseasemechanism of actionclinical application
耿研,谢希,王昱,等. 类风湿关节炎诊疗规范[J]. 中华内科杂志,2022,61(1):51-59.
GENG Y,XIE X,WANG Y,et al. The standardized diagnosis and treatment of rheumatoid arthritis[J]. Chin J Intern Med,2022,61(1):51-59.
张文,厉小梅,徐东,等.原发性干燥综合征诊疗规范[J].中华内科杂志,2020,59(4):269-276.
ZHANG W,LI X M,XU D,et al. Primary Sjögren syndrome diagnosis and treatment criteria [J]. Chin J Int Med,2020,59 (4) :269-276.
KONG R N,GAO J,JI L M,et al. Iguratimod ameliorates rheumatoid arthritis progression through regulating miR-146a mediated IRAK1 expression and TRAF6/JNK1 pathway:an in vivo and in vitro study[J]. Clin Exp Rheumatol,2021,39(2):289-303.
邓家鑫. 艾拉莫德对类风湿关节炎成纤维样滑膜细胞增殖、迁移的影响及临床疗效观察[D]. 广州:南方医科大学,2017.
DENG J X. Clinical efficacy observation and the influen-ces of iguratimod on fibroblast synovial cells proliferation and transfer in RA[D].Guangzhou:Southern Medical University,2017.
穆培霞,马玲,付冬冬,等. 艾拉莫德对类风湿关节炎滑膜细胞凋亡及炎症因子水平的影响[J]. 郑州大学学报(医学版),2020,55(3):364-368.
MU P X,MA L,FU D D,et al. Effects of iguratimod on apoptosis and inflammatory factor expressions of synovial cells isolated from synovial tissue of patients with rheumatoid arthritis[J]. J Zhengzhou Univ Med Sci,2020,55(3):364-368.
孔瑞娜. 艾拉莫德调控miR-146a介导的IRAK1/TRAF6/JNK1通路治疗类风湿关节炎的机制研究[D]. 上海:海军军医大学,2020.
KONG R N. Mechanism of iguratimod regulating IRAK1/TRAF6/JNK1 pathway mediated by miR-146a in the treatment of rheumatoid arthritis[D].Shanghai:Naval Medical University,2020.
齐晅,田玉,孙超,等. 艾拉莫德对干燥综合征小鼠颌下腺炎症及NF-κB信号通路的影响[J]. 中国免疫学杂志,2021,37(8):907-911.
QI X,TIAN Y,SUN C,et al. Effects of iguratimod on inflammation and NF-κB signaling pathway of submandibular gland in mice with Sjögren syndrome[J]. Chin J Immunol,2021,37(8):907-911.
XIA Y,FANG X,DAI X J,et al. Iguratimod ameliorates nephritis by modulating the Th17/Treg paradigm in pristane-induced lupus[J]. Int Immunopharmacol,2021,96:107563.
KOGA T,ICHINOSE K,KAWAKAMI A,et al. The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target[J]. Expert Rev Clin Immunol,2019,15(6):629-637.
刘娟. cGVHD狼疮样小鼠模型建立及基于TLR9/NF-κB/Nrf2信号通路对狼疮肾炎小鼠的干预研究[D]. 长春:吉林大学,2019.
LIU J. Establishment of a murine induced model with lupus-prone cGVHD and intervention study on lupus nephritis mice based on TLR9/NF-κB/Nrf2 signal pathway[D].Changchun:Jilin University,2019.
ZENG H Q,CHEN S,LU X P,et al. Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis[J]. Front Bioinform,2022,2:932114.
ZHAO C M,GU Y B,CHEN L Y,et al. Upregulation of FoxO3a expression through PI3K/Akt pathway attenuates the progression of lupus nephritis in MRL/lpr mice[J]. Int Immunopharmacol,2020,89(Pt A):107027.
蒋慧慧.撤热存津颗粒联合艾拉莫德治疗原发性干燥综合征高IgG的临床观察[D].长沙:湖南中医药大学,2021.
JIANG H H. Clinical observation on high IgG of Chere cunjin keli combined with iguratimod in the treatment of primary Sjögren syndrome[D]. Chagnsha:Hunan University of Chinese Medicine,2021.
任艳红,董伟,柳华,等. 艾拉莫德联合甲氨蝶呤治疗类风湿性关节炎的临床观察[J]. 中国药房,2017,28(32):4530-4533.
REN Y H,DONG W,LIU H,et al. Clinical observation of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis[J]. China Pharm,2017,28(32):4530-4533.
李玉娟,李红. 甲泼尼龙联合艾拉莫德治疗老年PSS患者的效果及其对免疫球蛋白水平的影响[J]. 辽宁医学杂志,2022,36(4):64-67.
LI Y J,LI H. Efficacy of methylprednisolone combined with iguratimod in the treatment of elderly patients with PSS and its effect on immunoglobulin levels[J]. Med J Liaoning,2022,36(4):64-67.
王雪,袁祥,王其凯,等. 艾拉莫德对原发性干燥综合征的治疗作用及其机制[J]. 中华疾病控制杂志,2018,22(1):75-78,84.
WANG X,YUAN X,WANG Q K,et al. Clinical study of effectiveness and safety of iguratimod in treating primary Sjögren syndrome[J]. Chin J Dis Contr Prev,2018,22(1):75-78,84.
XUE L X,XU J J,LU W T,et al. Iguratimod alleviates tubulo-interstitial injury in mice with lupus[J]. Ren Fail,2022,44(1):636-647.
庞琳烜,郑朝晖,李治琴,等. 艾拉莫德联合依那西普治疗强直性脊柱炎的疗效[J]. 热带医学杂志,2020,20(4):538-541.
PANG L X,ZHENG Z H,LI Z Q,et al. Curative effect of iguratimod combined with etanercept on ankylosing spondylitis[J]. J Trop Med,2020,20(4):538-541.
孙红丽,牛林,李兴,等. 艾拉莫德联合沙利度胺对强直性脊柱炎患者免疫球蛋白及ESR、C3、C4的影响[J]. 现代生物医学进展,2021,21(15):2943-2947.
SUN H L,NIU L,LI X,et al. Effects of elamud combined with thalidomide on immunoglobulin,ESR,C3 and C4 in patients with ankylosing spondylitis[J]. Prog Mod Biomed,2021,21(15):2943-2947.
张伟. 艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效[J]. 医学信息,2022,35(15):114-116.
ZHANG W. Efficacy of iguratimod combined with celecoxib in the treatment of ankylosing spondylitis[J]. J Med Inf,2022,35(15):114-116.
彭杨茜子,孔瑞娜,张兰玲,等. 基于Wnt/β-catenin信号通路的艾拉莫德对白介素1β诱导的大鼠退变软骨细胞基质代谢的影响研究[J]. 中国全科医学,2019,22(23):2826-2832.
PENG Y X Z,KONG R N,ZHANG L L,et al. Iguratimod regulation of matrix metabolism of rat degenerative chondrocytes induced by IL-1β through Wnt/β-catenin signaling pathway[J]. Chin Gen Pract,2019,22(23):2826-2832.
邓丽,文振华,田锋,等. 艾拉莫德通过TLR4/NF-κB通路抑制骨关节炎软骨细胞模型凋亡及炎症反应[J]. 国际检验医学杂志,2023,44(3):316-321.
DENG L,WEN Z H,TIAN F,et al. Iguratimod inhibits apoptosis and inflammatory response on osteoarthritis chondrocyte model by TLR4/NF-κB pathway[J]. Int J Lab Med,2023,44(3):316-321.
GAN K,YANG L L,XU L X,et al. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways[J]. Int Immunopharmacol,2016,35:294-300.
朱富,冯媛,林浩博,等. 艾拉莫德经Smad3/p300通路抑制转化生长因子β1介导的人肺成纤维细胞活化及胶原分泌[J]. 中华风湿病学杂志,2021,25(11):721-726.
ZHU F,FENG Y,LIN H B,et al. Iguratimod inhibits transforming growth factor-β1 induced human lung fibroblast activation and collagen secretion via the Smad3/p300 pathway[J]. Chin J Rheumatol,2021,25(11):721-726.
韩青,房志强,王振华,等. 艾拉莫德对肺纤维化小鼠肺组织的保护作用[J]. 中华临床免疫和变态反应杂志,2018,12(2):151-155.
HAN Q,FANG Z Q,WANG Z H,et al. Protective effect of iguratimod against bleomycin-induced pulmonary fibrosis mice[J]. Chin J Allergy Clin Immunol,2018,12(2):151-155.
赵丽珂,周荣伟,穆冰瑶,等. 艾拉莫德对博来霉素诱导的肺间质纤维化小鼠模型的影响[J]. 中华风湿病学杂志,2017,21(6):370-374.
ZHAO L K,ZHOU R W,MU B Y,et al. Effects of iguratimod on mice model of bleomycin-induced pulmonary fibrosis[J]. Chin J Rheumatol,2017,21(6):370-374.
ZHAO L K,MU B Y,ZHOU R W,et al. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9[J]. Int J Rheum Dis,2019,22(4):686-694.
郑健,张竞,王妍华,等. 真实世界接受IGU治疗的RA患者的人群特征、疗效及影响因素[J]. 西安交通大学学报(医学版),2021,7(4):580-584.
ZHENG J,ZHANG J,WANG Y H,et al. Characteristics,efficacy and influencing factors of RA patients treated with iguratimod in the real world[J]. J Xi’an Jiaotong Univ Med Sci,2021,7(4):580-584.
刘颖,林书典,潘楚瑛,等. 艾拉莫德对类风湿关节炎患者免疫功能及血清RF抗-CCP及Wnt-3α的影响[J]. 河北医学,2021,27(5):732-737.
LIU Y,LIN S D,PAN C Y,et al. Effects of iguratimod on immune function and serum RF anti-CCP and Wnt-3α in patients with rheumatoid arthritis[J]. Hebei Med,2021,27(5):732-737.
王燕,陈春强,高伟,等. 高频超声对艾拉莫德治疗类风湿关节炎疗效的评估[J]. 医学综述,2022,28(10):2055-2059.
WANG Y,CHEN C Q,GAO W,et al. Efficacy evaluation of iguratimod for treatment of rheumatoid arthritis with high frequency ultrasound imaging[J]. Med Recapitul,2022,28(10):2055-2059.
施卫民,刘棒,王文琴. 艾拉莫德联合改善病情的抗风湿药治疗类风湿关节炎合并骨质疏松的疗效分析[J]. 临床药物治疗杂志,2023,21(2):31-35.
SHI W M,LIU B,WANG W Q. Analysis of effect of iguratimod combined with disease-modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis complicated with osteoporosis[J]. Clin Med J,2023,21(2):31-35.
徐冬,吕晓伟,崔鹏,等. 艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性比较[J]. 疑难病杂志,2017,16(9):915-918.
XU D,LV X W,CUI P,et al. Comparison of the efficacy and safety of iguratimod and hydroxychloroquine in the treatment of primary Sjögren syndrome[J]. Chin J Difficult Complicat Cases,2017,16(9):915-918.
梁爽,姚胜,高紫欣,等. 艾拉莫德与羟氯喹治疗原发性干燥综合征有效性和安全性比较的系统分析[J]. 中国免疫学杂志,2022,38(5):591-598.
LIANG S,YAO S,GAO Z X,et al. Efficacy and safety of iguratimod and hydroxychloroquine for primary Sjögren syndrome:a meta-analysis[J]. Chin J Immunol,2022,38(5):591-598.
王艳玲,赵福涛,艾香艳,等. 艾拉莫德治疗老年原发性干燥综合征的疗效及安全性观察[J]. 老年医学与保健,2019,25(2):209-213.
WANG Y L,ZHAO F T,AI X Y,et al. Curative effect of iguratimod on primary Sjögren syndrome in the elderly and its safety[J]. Geriatr Health Care,2019,25(2):209-213.
张丽华,钟苗,李俏,等. 艾拉莫德治疗干燥综合征合并肺间质病变的疗效评价[J]. 中国现代药物应用,2019,13(20):1-3.
ZHANG L H,ZHONG M,LI Q,et al. Evaluation on efficacy of iguratimod on primary Sjögren syndrome complicated with pulmonary interstitial lesions[J]. Chin J Mod Drug Appl,2019,13(20):1-3.
何伟珍,张会昌,莫入,等. 艾拉莫德联合昆仙胶囊治疗难治性狼疮性肾炎1例[J]. 新医学,2020,51(1):71-73.
HE W Z,ZHANG H C,MO R,et al. Iguratimod combined with Kunxian capsule in treatment of refractory lupus nephritis:a case report[J]. J N Med,2020,51(1):71-73.
KANG Y N,YAN Q R,FU Q,et al. Iguratimod as an alternative induction therapy for refractory lupus nephritis:a preliminary investigational study[J]. Arthritis Res Ther,2020,22(1):65.
YAN Q R,DU F,KANG Y N,et al. Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis:study protocol for a multi-center,randomized,controlled clinical trial (iGeLU study)[J]. Trials,2021,22(1):530.
LONG Z Y,DENG Y,HE Q,et al. Efficacy and safety of iguratimod in the treatment of ankylosing spondylitis:a systematic review and meta-analysis of randomized controlled trials[J]. Front Immunol,2023,14:993860.
袁芳芳,陈亚慧,林吉霞,等. 艾拉莫德联合甲氨蝶呤治疗难治性强直性脊柱炎疗效及对患者血清SOD、CTX-Ⅰ水平影响[J]. 药物流行病学杂志,2020,29(3):163-165,205.
YUAN F F,CHEN Y H,LIN J X,et al. Therapeutic effect of elamode combined with methotrexate on refractory ankylosing spondylitis and its effect on SOD and CTX-Ⅰ[J]. Chin J Pharmacoepidemiol,2020,29(3):163-165,205.
徐亦文,陶伊丽,张华,等. 艾拉莫德治疗中轴型脊柱关节炎的临床疗效观察[J]. 上海医学,2021,44(6):421-424.
XU Y W,TAO Y L,ZHANG H,et al. Clinical effect of iguratimod for treatment of axial spondyloarthritis[J]. Shanghai Med J,2021,44(6):421-424.
0
浏览量
4
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构